INTRODUCTION
Ine⁄cient inhaler use has long been recognized as a major problem for many patients using pressurized metered dose inhalers (pMDIs) who have di⁄culty in co-ordinating actuation of the device with inhalation (1) . Such problems, together with the phasing out of the chloro£uorocarbon propellants used in the original formulations of MDIs, have resulted in the development of dry powder inhalers (DPIs). Patients generally ¢nd DPIs easier to use than pMDIs since they are breath-actuated and do not require co-ordination of actuation and inhalation. Furthermore DPI's operate without the need for potentially environmentally damaging propellants. However in vivo lung deposition can be in£uenced by the patient's inspiratory £ow rate, and this may be particularly relevant for patients with severe asthma, the elderly and young children (2) . Pulmicort Turbuhaler 1 (AstraZeneca, Lund, Sweden) is a multi-dose DPI that has been widely used for the delivery of budesonide powder. However, it is well documented that the amount of drug delivered from theTurbuhaler 1 varies greatly from dose to dose, and that particularly the ¢ne particle dose is reduced signi¢cantly when used with a low inspiratory £ow rate (3, 4) . Airmax TM is a trademark of Yamanouchi Europe BV (Leiderdorp, The Netherlands) for a novel multi-dose (200 doses) DPI, which utilizes proprietary technology known as the X-ACT TM system (Fig. 1 ). This active-metering, cyclone-separator technology was designed to provide accurate and consistent dosing to the patient largely independent of inspiratory e¡ort. Unlike other devices which rely on gravity, X-ACT TM uses controlled air pressure from an internal pump to exactly meter the dose. The inhaler is simply operated by opening the mouthpiece cap, inhaling and closing again. Closing of the cap triggers the precise dose counter. When the patient inhales, the dose is transported into the cyclone separator, which separates the drug from its lactose carrier and produces a high ¢ne particle dose. Gravimetric studies and studies with multi-stage liquid impingers have shown typical relative standard deviations of dose consistency of 5%, emitted doses between 901 05% of label claim and ¢ne particle fractions between 49^59% (5,6).
The aim of the present study was to con¢rm the in vitro results using a validated gamma scintigraphic technique (7^9), and to compare the delivery of budesonide from Airmax TM with that from Turbuhaler 1 at di¡erent £ow rates and with that from a pMDI. In order to make the data as clinically relevant as possible, results were expressed both as percentage of delivered dose and as mass of budesonide deposited in the lungs.
METHODS STUDY POPULATION
Sixteen volunteers aged 18^55 years with a diagnosis of asthma at least 6 months prior to study entry were screened, of whom 13 were subsequently entered into the study. All patients had within the previous 2 years demonstrated a forced expiratory volume in 1sec (FEV 1 ) at least 60% predicted for their height and gender, and a reversibility of at least 10% in FEV 1 following inhalation of a standard 200 mg dose of salbutamol from a pMDI. Patients were excluded if they had upper or lower respiratory tract infection within the previous 2 weeks. All patients gave written informed consent to their participation after full explanation of the nature of the study, which was approved by the Quorn Research Review Committee, Leicestershire,UK, and performed in accordance with the Declaration of Helsinki. 
STUDY DESIGN

RADIOLABELLING OF BUDESONIDE
Budesonide from the Turbuhaler 1 was radiolabelled as described previously (10) . Brie£y, the radiolabel ( 99m Tc) was extracted from saline into methyl ethylketone, and after removal of the solvent by evaporation, was redissolved in water and mixed with budesonide powder.The water was then removed by freeze-drying and the radiolabelled powder transferred to an empty Turbuhaler. For Airmax TM , a similar method was used to obtain radiolabelled budesonide powder, 100 mg of which was blended with lactose (2050 mg) in a Turbula mixer (42 rpm) for 30 min. Each Airmax TM device was ¢lled with 730 mg of this blend.
The method for the pMDI was as follows: the radiolabel ( 99m Tc) was extracted into methyl ethylketone and transferred to an empty pMDI canister. After removal of the solvent the contents of a full canister previously cooled in liquid nitrogen were added to the residue and a new metering valve was crimped in place.The canister was sonicated for 10 min in order to ensure even dispersion of the radiolabel throughout the formulation.
In order to show that the radiolabel was a valid marker for budesonide, the size distributions of drug before labelling, of drug after labelling and of objective was to show that the size distributions of the products were not changed signi¢cantly by the radiolabelling procedure, and that the radiolabel and drug matched one another across the full range of particle size bands.
GAMMA SCINTIGRAPHY
Immediately following administration of the radiolabelled formulation, posterior and anterior views of the chest and a right lateral view of the oropharynx were recorded using a gamma camera (General Electric Maxicamera, Milwaukee, WI, U.S.A.) connected to a Park Medical computer system (Farnborough, U.K.). On one study day, unless available from a previous study within the previous 2 years, a posterior lung ventilation scan was performed on each patient using the radioactive inert gas 81m Kr in order to de¢ne the edges of the lung ¢elds.The lungs were subdivided into central, intermediate and peripheral regions of interest as previously described (11), thus enabling the percentage of the dose in each lung zone to be determined and the peripheral lung zone /central lung zone deposition ratio to be calculated. The counts obtained within these regions were corrected for background radioactivity, radioactive decay, acquisition time and for tissue attenuation of gamma rays (12) . In regions where both anterior and posterior images were recorded, the geometric mean of counts in both images was calculated prior to correction for tissue attenuation. Deposition in the oropharynx included activity adhering to the mouth and oropharynx together with any swallowed activity detected in the oesophagus, stomach and intestine and activities deposited on the mouthpiece of the exhalation ¢lter. Since the mouthpiece of the Airmax TM cannot be separated from the body of the device, it was not possible to quantify deposition on the Airmax TM mouthpiece. Data for all three devices were expressed as percentage of delivered (emitted) dose from the sum of corrected total body counts and those on the exhaled air ¢lter.
The actual masses of budesonide deposited in the lungs were calculated by using actual delivered masses at the relevant £ow rates determined by in vitro analysis. Using an HPMLI delivered doses at the £ow rates of 60 l min 71 and 30 l min 71 for each DPI (n = 3) were ¢rst determined. Mean dose delivered by the pMDI was assumed to be equal to the nominal dose of 200 mg. Lung deposition values expressed as mass of budesonide were calculated as (% delivered dose in lungs) 6 (mean measured delivered dose) / 100.
STATISTICAL ANALYSIS
The study was designed to detect di¡erences between the patterns of lung deposition from di¡erent devices at the two £ow rates. Since clinically relevant di¡erences were unknown, an arbitrary 4% di¡erence in total lung deposition was selected for power calculations. Based on previous studies which had demonstrated whole lung deposition of a range of inhalers averaging 15% of the dose, with a standard deviation of 3% of the dose, it was calculated that 10 evaluable patients would be needed to detect a di¡erence of 4% with a = 0?05 and a power of 80%.
Three contrasts were de¢ned and were statistically analysed using analysis of variance (ANOVA)
RESULTS
RADIOLABELLING VALIDATION
The results of the radiolabelling validation experiments are shown in Table 1 . For all devices there was a good match between the ¢ne particle fractions (FPFs) of delivered dose for the drug before labelling, the drug after labelling and the radiolabel itself. Hence the radiolabel was considered to be a valid marker for the drug for all three products. The radiolabel FPFs of the inhalers used on study days were determined before dosing, and were shown to be within the range of values determined in the prestudy validation testing.
PATIENTS
Demographic variables of the patients are shown in Table 2 . Of the 13 patients that entered the study, 12 completed the 60 l min 71 arms with the DPIs and11 completed the 30 l min 71 arms. 22?7+5?6% of the delivered dose in the whole lung. The small increase in deposition for Airmax TM at the lower £ow rate was not statistically signi¢cant (P = 0?208), whereas the decrease in performance at lower £ow rate for Turbuhaler 1 was signi¢cant (P = 0?003). Whole lung deposition was lowest for the pMDI (12?1 +3?4%), while oropharyngeal deposition was highest (86?8 + 3?8%) with the pMDI.Regional deposition patterns were similar for all treatments with the peripheral zone being the (Fig. 3) . As with percentage deposition data, the estimated mass of budesonide deposited in the whole lungs with Airmax TM did not di¡er signi¢cantly from the mass deposited by Turbuhaler 1 at 60 l min 
Inhalation manoeuvres and lung function
Safety
A total of 11 mild to moderate adverse events were reported by nine patients, of whom ¢ve reported adverse events before the ¢rst treatment period. Adverse events included headache, rhinitis and conjunctivitis. None of these were considered to be related to the study medication or procedures. There were no serious adverse events. There was no evidence of bronchoconstriction for any of the study regimens.
DISCUSSION
The present study showed that the novel multi-dose dry powder inhaler, Airmax TM , deposited a mean 26% of the delivered dose (mean 53 mg budesonide) in the lungs at the fast £ow rate of 60 l min
71
. This amount is similar to that delivered by Turbuhaler 1 at this £ow rate. At low inhaled £ow rate (30 l min
) the performance of Airmax TM remained virtually unchanged, whereas Turbuhaler 1 delivered signi¢cantly less budesonide. Both dry powder inhalers were superior to pMDI when used at high inspiratory £ow rates. The regional lung distribution patterns were broadly similar between the di¡erent inhalers and £ow rates investigated.
The data obtained in the present study are consistent with those obtained in previous studies with Turbuhaler 1 and pMDIs. At a peak inspiratory £ow rate (PIFR) of 60 l min
, lung deposition from the Turbuhaler 1 averages between 14% and 32% of the metered dose (13^17). A halving of PIFR to 30 l min 71 has been shown previously to approximately halve lung deposition (16), while lung deposition from a budesonide pMDI has been shown to be approximately half of that from a Turbuhaler 1 (13, 14) , when bothTurbuhaler 1 and pMDI were used optimally.
In the present study there was a close match between actual PIFR and target values for Turbuhaler , respectively) observed in in vitro studies (Table 1 ) when both inhalers are tested at a pressure drop of 4 kPa as required by Pharmacopoeial guidelines (18) .This di¡er-ence is caused by the higher internal resistance of theTurbuhaler 1 . This suggests that the inspiratory e¡ort applied by the patients in this trial was similar for both Airmax TM and Turbuhaler 1 and hence the comparison is justi¢ed.
The use of gamma scintigraphy, as other imaging techniques, does not allow direct quanti¢cation of the mass of drug deposited. In order to understand as fully as possible the clinical relevance of our ¢ndings, we estimated lung deposition expressed not only as percentage of delivered dose, but also as mass of budesonide deposited into the lungs, based on separate laboratory measurements of delivered (emitted) dose. In our in vitro analysis we showed that Airmax TM delivered 103% of the label claim at 60 l min 71 and 77% at 30 l min
, hence there was a drop in estimated mean mass deposited in the lungs of about10 mg when the £ow rate through the Airmax was halved. For Turbuhaler 1 this drop in performance was accentuated as the in vitro method showed that at 60 l min 71 typically only 80% of the label claim was emitted and at 30 l min 71 this dropped to 54% of the label claim. These data were consistent with those reported by other investigators (15, 16) . As a consequence partly of reduced percentage deposition, and partly of reduced delivered dose, the mass of budesonide deposited in the lungs was halved when the inhaled £ow rate through the Turbuhaler 1 was reduced from 60 l min 71 to 30 l min
. Lung deposition of budesonide from Turbuhaler 1 at 30 l min 71 was similar at around 24 mg to lung deposition achieved by the pMDI at this £ow rate.
There have been few studies to quantify the mass of drug deposited into the lungs through imaging techniques, and expressing the results in this way may give a better correlation with clinical ¢ndings. Hence the results of lung deposition studies may be considered as a 'bridge' between the in vitro testing programme and clinical trials carried out to assess the e⁄cacy of a novel product in man (19) . The clinical response to inhaled anti-asthma drugs may depend not only upon the total amount of drug deposited in the lungs, but also upon the regional deposition pattern within the airways (20) . This was expressed in the present study as the peripheral/central (P/C) ratio which has been shown to correlate with the relative amounts of drug deposited in the tracheobronchial and alveolated airways of the lungs (21) . The similar P/C ratios for Airmax TM and Turbuhaler 1 in this study suggest that both devices fractionate the dose between the two major anatomical regions of the lungs in a broadly similar manner. The P/C ratios in this study were more typical of those often seen in healthy subjects, despite this being a patient study. This could be a result of the predose administration of salbutamol, which was done in order to minimise day-to-day variation in lung function in this cross-over study.
We conclude that lung deposition of budesonide from Airmax TM and Turbuhaler 1 are similar when used by patients at 'fast' inspiratory £ows of 60 l min 71 . However, lung deposition from Airmax TM at low £ow rates is markedly superior to both Turbuhaler 1 and pMDI.UnlikeTurbuhaler1, Airmax TM DPI performs relatively independently of £ow rate and hence inspiratory e¡ort.
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